Enhancing the immunomodulatory capacity and therapeutic potential of mesenchymal stromal cell-derived small extracellular vesicles through cytokine licensing
View/ Open
Date
2023-09-12Embargo Date
2025-08-31
Author
Donohoe, Ellen
Metadata
Show full item recordUsage
This item's downloads: 0 (view details)
Abstract
The immunomodulatory capacity of mesenchymal stromal cells (MSCs) is well
established, and is being explored as a cellular therapy for the treatment of various
inflammatory-based conditions. In recent years, the role of the MSC secretome in
mediating the observed efficacy of MSC has come to light, with their secreted small
extracellular vesicles (sEV) receiving particular attention. MSC potency can be
enhanced by cytokine licensing, a strategy in which MSCs are exposed to cytokines
prior to administration to promote their secretion of various immunoregulatory
factors. However, the effects of cytokine licensing on the characteristics and
biomolecular cargo of MSC-sEV have not yet been well established. Given that
cytokine licensing elevates the immunomodulatory status of the parent cell, it
should also be explored whether this also impart superior functionality to their
secreted sEV. The aim of this project was to investigate the effects of two different
cytokine licensing strategies on MSC-sEV, based on alterations in their cargo and
therapeutic potency in vitro and in vivo in a murine model of corneal chemical burn.
In order to generate cytokine licensed cells, BALB/c MSCs were cultured with no
supplement, recombinant IFNγ, or recombinant TGFβ1 for 72h to generate MSC,
MSCIFNγ
, and MSCTGFβ
, respectively. sEV, sEVIFNγ
, and sEVTGFβ were then isolated
from the conditioned medium of the parental cells by a combination of
ultrafiltration and size exclusion chromatography. MSCTGFβ, but not MSCIFNγ
,
yielded increased secretion of sEV compared to unlicensed MSC. Relative to
unlicensed sEV, sEVIFNγ exhibited increased expression of MHC I and PD-L1 on
their surface, whereas sEVTGFβ expressed higher levels of CD44, CD29, and CD73.
Furthermore, cytokine licensing resulted in enrichment of specific miRNAs in the
secreted sEV, and the different licensing strategies each induced unique therapeutic
potentials based on functional enrichment analysis of overexpressed miRNA
transcripts.
In order to assess the immunomodulatory capacity of the isolates, sEV, sEVIFNγ
,
and sEVTGFβ were cultured with stimulated allogeneic macrophages and T cells in
various in vitro assays. Only sEVTGFβ was found to reduce macrophage expression
of antigen presentation machinery MHC II and CD80, and induced the secretion of
M2-like cytokines to a higher degree than sEV and sEVIFNγ
. sEVTGFβ were also found to increase Treg expansion and FOXP3 expression, indicative of enhanced
Treg suppressive activity. In contrast, neither sEV nor sEVIFNγ elicited any
significant induction of Treg activity. In a 2D scratch assay, sEVTGFβ, but not sEV
or sEVIFNγ, accelerated wound healing in corneal epithelial cells and corneal
endothelial cells.
Given the superior efficacy observed of sEVTGFβ in vitro, this product was brought
forward for in vivo testing in a mouse model of corneal chemical burn. Corneal
injury was induced by placing a 1.5mm2
filter paper soaked with 1M NaOH on the
central cornea for 30 seconds, following which the eye was irrigated with PBS.
sEVTGFβ were applied either topically (day 0, 1, and 3) or subconjunctivally (day 0,
and 3), and mice were monitored for 14 days. sEVTGFβ
, particularly when delivered
subconjunctivally, ameliorated burn-induced structural damage and accelerated
restoration of normal corneal thickness, compared to PBS-treated controls. sEVTGFβ
by either administration route also resulted in reduced inflammatory mediators (IL1β, iNOS) and minimised levels of fibrosis-associated collagen in the cornea at day
14. Immune cells of the draining lymph nodes in mice that received
subconjunctival, but not topical, administration of sEVTGFβ exhibited regulatory
profiles with reduced M1-like macrophages, increased M2-like macrophages, and
restored Treg function and balance of the Treg/Th17 axis.
Overall, different cytokine licensing strategies were found to yield unique MSCsEV phenotypes with differing potencies in the context of immunomodulation.
Cytokine licensing with TGFβ1 was found to enhance the therapeutic efficacy of
MSC-sEV, with sEVTGFβ representing an immunomodulatory therapy with
significant potential as an off-the-shelf clinical product.